Premium
Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response
Author(s) -
Rohatgi Pooja,
Swisher Stephen G.,
Correa Arlene M.,
Wu TsungT.,
Liao Zhongxing,
Komaki Ritsuko,
Walsh Garrett L.,
Vaporciyan Ara A.,
Rice David C.,
Roth Jack A.,
Ajani Jaffer A.
Publication year - 2005
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.21439
Subject(s) - medicine , chemoradiotherapy , stage (stratigraphy) , carcinoma , esophageal cancer , esophagus , radiation therapy , esophagectomy , cancer , chemotherapy , oncology , gastroenterology , surgery , paleontology , biology
BACKGROUND The purpose of the current study was to test the hypothesis that a lower clinical TNM stage is associated with a higher rate of pathologic complete response (pathCR) in patients with esophageal carcinoma receiving preoperative chemoradiotherapy and to determine whether outcome after pathCR is related to clinical stage or treatment. METHODS Clinical parameters and surgical specimens of patients with esophageal carcinoma undergoing preoperative chemoradiotherapy were analyzed to identify predictors of pathCR. In patients with pathCR, predictors of overall survival (OS), disease‐free survival (DFS), and distant recurrence were studied. RESULTS Sixty‐nine (29%) of 235 patients achieved pathCR. In patients with American Joint Committee on Cancer (AJCC) Stage II carcinoma, the proportion achieving pathCR was significantly larger than that achieving